- Safety & Recalls
- Regulatory Updates
- Drug Coverage
- COPD
- Cardiovascular
- Obstetrics-Gynecology & Women's Health
- Ophthalmology
- Clinical Pharmacology
- Pediatrics
- Urology
- Pharmacy
- Idiopathic Pulmonary Fibrosis
- Diabetes and Endocrinology
- Allergy, Immunology, and ENT
- Musculoskeletal/Rheumatology
- Respiratory
- Psychiatry and Behavioral Health
- Dermatology
- Oncology
FDA Pipeline preview, November 2008 (aztreonam lysine, fentanyl buccal, tocilizumab, everolimus, ENB-0040, artemether/lumefantrine)
Recent FDA action (through November 2008) related to aztreonam lysine, fentanyl buccal, tocilizumab, everolimus, ENB-0040, and artemether/lumefantrine
Complete responses
• Aztreonam lysine for inhalation (Gilead) for the treatment of Pseudomonas aeruginosa infection in patients with cystic fibrosis (CF)
• Fentanyl buccal tablet (Fentora, Cephalon) for the treatment of noncancer breakthrough pain in opioid-tolerant patients
• Tocilizumab (Actemra, Roche) for the treatment of moderate-to-severe rheumatoid arthritis (RA)
Priority review
• Recombinant form of human antithrombin (ATryn, GTC) for the prophylactic treatment of deep vein thrombosis (DVT) and other thromboembolisms in patients with hereditary antithrombin deficiency who are undergoing high-risk surgical or childbirth procedures
• Artemether/lumefantrine (Coartem, Novartis) for the treatment of malaria
• Everolimus (Novartis) for the treatment of advanced kidney cancer after failure of standard treatment
Orphan drug designation
• ENB-0040 (Enobia) for the treatment of hypophosphatasia
Payers Recognize the Benefits, but Still See Weight Loss Drugs through a Cost Lens
April 12th 2024Jeffrey Casberg, M.S., R.Ph., a senior vice president of clinical pharmacy at IPD Analytics LLC, a drug intelligence firm that advises payers and pharmaceutical companies, talks about how payers are thinking about weight-loss drugs.
